Science

A Scientific Breakthrough - Saving Lives by Reversing Hypotension

Millions of people around the world suffer from low blood pressure and the risk of organ failure, with few solutions. Rallidae's unique V1aR partial agonists are the answer — safely restoring normal blood pressure, eliminating dangerous over-constriction, and selectively targeting V1a receptors for unmatched safety and efficacy.

OUR SCIENTIFIC PROGRESS

Our scientific progress is driven by a focus on high-impact solutions for kidney health. We bridge the gap between complex biology and practical medicine to create life-changing therapies.

Partner With Us

PHASE 2 CLINICAL

Acute hypotension

PROGRAM

OCE-205

OCE-205 is a first generation partial agonist of the vasopressin V1aR, delivered IV, with efficacy broadly validated, including human clinical studies demonstrating safety, with no sign of ischemia, and efficacy, with an improvement in patient renal function.

Croston et al in vitro

Rat efficacy

Rat and NHP PK and PD

Phase 1 clinical

Phase 2 clinical

Discovery

Chronic Kidney Disease

Chronic Liver Disease

Chronic Hypotension

PROGRAM

OCE-205

V1aR partial agonists that are stabilized for SC delivery With SC outpatient delivery, V1aR partial agonists can reach far more patients with hypotension in large therapeutic areas.

Liver Crisis

800

K+

Patients in the US living with decompensated cirrhosis

Clinical Validation

Transforming Care in Cirrhotic Liver Disease

Terlipressin has validated V1aR for decades in decompensated cirrhosis, establishing a proven therapeutic foundation for Rallidae’s next-generation V1aR partial agonists.

Proven Mechanism

V1aR activation is clinically validated to improve circulatory function and organ perfusion in decompensated cirrhosis.

Improved Safety

Partial agonists are designed to reduce ischemia risk and improve selectivity compared to full agonist therapies.

Expanded Patient Access

Subcutaneous outpatient delivery could extend treatment access to significantly more patients across chronic disease populations.